financetom
Business
financetom
/
Business
/
American Outdoor Brands Q1 sales miss estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American Outdoor Brands Q1 sales miss estimates
Sep 4, 2025 2:34 PM

Overview

* The outdoor sporting goods retailer's Q1 fiscal 2026 sales fall 28.7%, missing estimates, per LSEG data

* American Outdoor Brands ( AOUT ) reports Q1 GAAP net loss of $6.8 mln, widening from last year

* Co repurchases 240,000 shares for $2.5 mln, ends quarter debt-free

Outlook

* Company expects near-term environment to reflect shifting market conditions

* American Outdoor Brands ( AOUT ) anticipates evolving consumer trends to impact results

* American Outdoor Brands ( AOUT ) remains cautious about quarterly fluctuations

Result Drivers

* ORDER ACCELERATION - Retailers accelerated orders into Q4 to avoid tariff-related price changes, impacting Q1 sales

* NEW PRODUCTS - New products accounted for nearly 29% of net sales, highlighting innovation focus

* RETAILER PURCHASING PATTERNS - Sales decline influenced by retailer purchasing patterns optimizing pricing and cash flows

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Sales Miss $29.70 $35.80

mln mln (2

Analysts

)

Q1 Net -$6.83

Income mln

Q1 Gross $13.86

Profit mln

Q1 $20.68

Operatin mln

g

Expenses

Q1 -$6.82

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the recreational products peer group is "buy"

* Wall Street's median 12-month price target for American Outdoor Brands Inc ( AOUT ) is $16.50, about 37.9% above its September 3 closing price of $10.24

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing
Mar 20, 2024
07:37 AM EDT, 03/20/2024 (MT Newswires) -- Hunter C Smith, Chief Financial Officer, on March 19, 2024, sold 15,515 shares in Rhythm Pharmaceuticals ( RYTM ) for $608,498. Following the Form 4 filing with the SEC, Smith has control over a total of 97,939 shares of the company, with 97,939 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1649904/000110465924036319/xslF345X03/tm249308-6_4seq1.xml ...
Norfolk Southern Appoints John Orr as Chief Operating Officer
Norfolk Southern Appoints John Orr as Chief Operating Officer
Mar 20, 2024
08:28 AM EDT, 03/20/2024 (MT Newswires) -- Norfolk Southern ( NSC ) said Wednesday it has appointed John Orr as executive vice president and chief operating officer, effective immediately, replacing Paul Duncan. Orr joins the company from Canadian Pacific Kansas City ( CP ) , where he was the chief transformation officer, the company said. Duncan departed the company to...
Atlassian Insider Sold Shares Worth $1,625,501, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,625,501, According to a Recent SEC Filing
Mar 20, 2024
08:27 AM EDT, 03/20/2024 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, Co-CEO, Co-Founder, on March 18, 2024, sold 8,241 shares in Atlassian ( TEAM ) for $1,625,501. Following the Form 4 filing with the SEC, Farquhar has control over a total of 65,928 shares of the company, with 65,928 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024002805/xslF345X03/primarydocument.xml Price: 197.2, Change: +0.77,...
Vera Therapeutics' 2023 Loss Narrows
Vera Therapeutics' 2023 Loss Narrows
Mar 20, 2024
08:26 AM EDT, 03/20/2024 (MT Newswires) -- Vera Therapeutics ( VERA ) reported a 2023 loss Wednesday of $2.25 per diluted share, narrower than a loss of $3.35 a year earlier. Analysts polled by Capital IQ expected a loss of $2.18. As expected, no revenue for the year ended Dec. 31 was reported. The company said it ended the year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved